Clinical implications of thiopurine methyltransferase - Optimization of drug dosage and potential drug interactions

Therapeutic Drug Monitoring

Volumn 20, Issue 5, 1998, Pages 527-531

  Lennard, Lynne ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Azathioprine; Mercaptopurine; Pharmacogenetics; Thioguanine; Thiopurine Methyltransferase

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ACETYLSALICYLIC ACID; AZATHIOPRINE; DISULFIRAM; MERCAPTOPURINE; MESALAZINE; SALAZOSULFAPYRIDINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ALCOHOLISM; CONFERENCE PAPER; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENOTYPE; HUMAN; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL;

6-MERCAPTOPURINE; ANTIMETABOLITES, ANTINEOPLASTIC; AZATHIOPRINE; DRUG INTERACTIONS; HUMANS; METHYLTRANSFERASES; PURINES; THIOGUANINE;

EID: 0031663491     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199810000-00014     Document Type: Conference Paper

References (33)

1. Glauser TA, Kerremans AL, Weinshilboum RM. Human hepatic microsomal thiol methyltransferase: assay conditions, biochemical properties and correlation studies. Drug Metab Dispos 1992;20: 247-55.
2. Deininger M, Szumlanski CL, Otterness DM, van Loon J, Ferber W, Weinshilboum RM. Purine substrates for human thiopurine methyltransferase. Biochem Pharmacol 1994;11:2135-8.
3. Woodson LC, Ames MM, Selassie CD, Hansch C, Weinshilboum RM. Thiopurine methyltransferase: aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol Pharmacol 1983;24: 471-8.
4. Lilleyman JS, Lennard L. 6-Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994; 343:1188-90.
5. Lennard L, Lilleyman JS, Van Loon JA, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-9.
6. Lennard L, Gibson BES, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993;69:577-9.
7. Lennard L, Lewis IJ, Michelagnoli M, Lilleyman JS. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-Mercaptopurine dosage strategies. Med Pediatr Oncol 1997;29:252-5.
8. McLeod HL, Relling MV, Liu Q, Pui C-H, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with ALL. Blood 1995; 7:1897-1902.
9. Lennard L, Welch J, Lilleyman JS. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br J Clin Pharmacol 1997;44:455-61.
10. Lennard L, Murphy MF, Maddocks JL. Severe megaloblastic leukaemia associated with abnormal azathioprine metabolism. Br J Clin Pharmacol 1984;17:171-2.
11. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46: 149-54.
12. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts VM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase deficient child with acute lymphoblastic leukaemia. J Pediatr 1991;119:985-9.
13. Schutz E, Gummert J, Mohr F, Armstrong VW, Oellerich M. Azathioprine myelotoxicity related to elevated 6-thioguanine nucleotides in heart transplantation. Transplant Proc 1995;27:1298-1300.
14. Anstey A, Lennard L, Mayou SC, Kirby JD. Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism: a review. J R Soc Med 1992;85:752-6.
15. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
16. Weinshilboum RM. Methylation pharmacogenetics: thiopurine methyltransferase as a model system. Xenobiotica 1992;22:1055-71.
17. Klemetsdal B, Straume B, Wist E, Aarbakke J. Identification of factors regulating thiopurine methyltransferase activity in a Norwegian population. Eur J Clin Pharmacol 1993;44:147-52.
18. McLeod HL, Lin J-S, Scott EP, Pui C-H, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharm Ther 1994;55:15-20.
19. Park-Hah JO, Klementsdal B, Lyssa R, Choi KH, Aarbakke J. Thiopurine emthyltransferase activity in a Korean population sample of children. Clin Pharmacol Ther 1996;60:68-74.
20. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1982;2:148-59.
21. Klemetsdal B, Tollefsen E, Loennechen T, et al. Interethnic differences in thiopurine methyltransferase activity. Clin Pharmacol Ther 1992;51:24-31.
22. Lee D, Szumlanski C, Houtman J, et al. Thiopurine methyltransferase pharmacogenetics: cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metab Dispos 1995;23:398-405.
23. Szumlanski C, Otterness D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996;15:17-30.
24. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997;62:60-73.
25. Yates CR, Krynetski EY, Loennechen T, et al. Molecular basis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126:608-14.
26. Tai H-L, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci 1997;94:6444-9.
27. Giverhaug T, Klemetsdal B, Lysaa, Aarbakke J. Intraindividual variability in red blood cell thiopurine methyltransferase activity. Eur J Clin Pharmacol 1996;50:217-20.
28. Lysaa RA, Giverhaug T, Wold HL, Aarbakke J. Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol 1996;49:393-6.
29. Pazmino PA, Sladek SL, Weinshilboum RM. Thiol S-methylation in ureamia: erythrocyte enzyme activities and plasma inhibitors. Clin Pharmacol Ther 1980;28:356-67.
30. Glauser TA, Nelson MD, Zembower DE, Lipsky JJ, Weinshilboum RM. Diethylthiocarbamate S-methylation: evidence for catalysis by human liver thiol methyltransferase and thiopurine methyltransferase. J Pharmacol Exp Ther 1993;266:23-32.
31. Szumlanski C, Weinshilboum RM. Sulfsalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39: 456-9.
32. Present DH, Korelitz BI, Wisch N, Glass JL, Sacher DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine: a long-term randomized double blind study. N Engl J Med 1980; 302:981-7.
33. Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow, suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997;62:464-75.